posted on 2005-11-03, 00:00authored byConrad W. Hummel, Andrew G. Geiser, Henry U. Bryant, Ilene R. Cohen, Robert D. Dally, Kin Chiu Fong, Scott A. Frank, Ronald Hinklin, Scott A. Jones, George Lewis, Denis J. McCann, Daniel G. Rudmann, Timothy A. Shepherd, Hongqi Tian, Owen B. Wallace, Minmin Wang, Yong Wang, Jeffrey A. Dodge
The design of a novel selective estrogen receptor
modulator (SERM) for the potential treatment of uterine
leiomyoma is described. 16 (LY2066948−HCl) binds with high
affinity to estrogen receptors α and β (ERα and ERβ, respectively) and is a potent uterine antagonist with minimal effects
on the ovaries as determined by serum biomarkers and
histologic evaluation.